
When Lisa Spain started Rexana's Foundation in 2006 after losing her closest friend to lung cancer just 60 days after diagnosis, the treatment landscape looked dramatically different than it does today.
Leah Phillips, a never-smoker with stage IV lung cancer driven by an EGFR exon 19 mutation, is a co-founder of the Young Lung Cancer Initiative.

When Lisa Spain started Rexana's Foundation in 2006 after losing her closest friend to lung cancer just 60 days after diagnosis, the treatment landscape looked dramatically different than it does today.

A lung cancer diagnosis comes with a flood of information, appointments, and decisions — often all at once, often before a patient feels ready.

There is a particular kind of fear that settles in after a lung cancer diagnosis — not just fear of the disease, but fear of the waiting.

Understand the difference between targeted therapy, chemotherapy, and immunotherapy in lung cancer — and why starting the wrong treatment first can be harmful for patients with targetable mutations.

Learn why comprehensive biomarker testing is essential before starting any lung cancer treatment. Hear from patients and oncologists about the life-changing importance of knowing your mutation first.

Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer.

September 6th 2025